NURS 5334 ANTIMICROBIAL FINAL EXAM
2026/2027 QUESTIONS AND CORRECT
ANSWERS GRADED A+ UTA
53 y/o woman with history of esophageal stricture—recently treated successfully
with dilatation—from
longstanding GERD, and vasomotor symptoms of menopause. A recent DEXA
showed a T score of -2.5 of
the LS spine and -2.6 in the left hip. Which therapy is MOST appropriate?
A. Prolia [Denosumab] 60 mg SQ every 6 months
B. Evista [Raloxifene] 60 mg po daily
C. Actonel [Risedronate] 35 mg po weekly
D. Boniva [Ibandronate] 150 mg po monthly
E. Calcitonin 200 units alternate nares qd
A. Prolia [Denosumab] 60 mg SQ every 6 months
38 y/o woman who is at a health fair. She asks what she can do tomaintain her
bone health. Her mum had severe osteoporosis with vertebral fractures, spinal
kyphosis, hip fracture and limited mobility. Your patient is 64 inches tall and
weighs 115 pounds. She is postmenopausal. Her meds include OCP and a
multivitamin daily; her DEXA scan shows a T score of 1.3 and a Z score of -.8.
which exercise regimen is going to be most helpful to improve her bone health?
A. Stair climbing
B. Cycling
C. Water aerobics
D. Yoga
,E. Spin class
F. Running
G. A, D and F
H. A and F
G. A, D and F
68 y/o man with several risk factors for osteoporosis— cigarette smoking, drinking
3-5 alcoholic drinks/day, low body weight and sedentary lifestyle. Labs reveal a 25
Vitamin D level of 18 mcg. Of the following, what will you recommend?
A. Increase dietary intake of milk, eggs and catfish
B. Increase sun exposure
C. Calcium citrate with Vitamin D [200/200 IU] BID
D. Vitamin D2 50,000 IU daily for 6-12 months
E. Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then
5,000 IU thereafter
E. Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then 5,000 IU thereafter
Which agent [s] has/have a low likelihood of causing CV adverse effects in a
patient with BPH who is also taken meds for HTN?
1. Alfuzosin [Uroxatrol]
2. Tamulosin [Flomax]
3. Finasteride [Proscar]
A. 1 only
B. 2 only
,C. 3 only
D. 1 and 3
E. 2 and 3
F. 1, 2 and 3
E. 2 and 3
Stimulation of muscarinic cholinergic receptors in thbladder muscle may be
responsible for:
A. Functional incontinence
B. Urge incontinence
C. Bladder overactivity
D. Bladder underactivity
E. Both B and C are correct
Both B and C are correct
Which of the following drugs in most appropriate for managing incontinence
related to bladder overactivity?
A. Imipramine
B. Estrogens
C. Pseudoephedrine
D. Oxybutynin
E. Bethanechol
D. Oxybutynin
, Which of the following distinguishes the phosphodiesterase type 5 [PDE-5]
inhibitor Tadalafil
[Cialis] from the other inhibitors Sildenafil [Viagra] and Vardenafil [Levitra]?
A. Efficacy
B. Safety
C. Duration of Action
D. All of the above
C. Duration of Action
Which of the following is NOT a desired characteristic of a therapy for ED?
A. Leads to a prolonged erection [>4 hours]
B. Minimal side effects
C. Convenient administration
D. Quick onset of action
E. Few drug interactions
A. Leads to a prolonged erection [>4 hours]
What is the MOA of the PDE-5 inhibitors?
A. Increase prostaglandin production
B. Enhance effect of nitric oxide
C. Cause vasoconstriction of the erection chamber
D. Antagonize cyclic GMP
B. Enhance effect of nitric oxide
2026/2027 QUESTIONS AND CORRECT
ANSWERS GRADED A+ UTA
53 y/o woman with history of esophageal stricture—recently treated successfully
with dilatation—from
longstanding GERD, and vasomotor symptoms of menopause. A recent DEXA
showed a T score of -2.5 of
the LS spine and -2.6 in the left hip. Which therapy is MOST appropriate?
A. Prolia [Denosumab] 60 mg SQ every 6 months
B. Evista [Raloxifene] 60 mg po daily
C. Actonel [Risedronate] 35 mg po weekly
D. Boniva [Ibandronate] 150 mg po monthly
E. Calcitonin 200 units alternate nares qd
A. Prolia [Denosumab] 60 mg SQ every 6 months
38 y/o woman who is at a health fair. She asks what she can do tomaintain her
bone health. Her mum had severe osteoporosis with vertebral fractures, spinal
kyphosis, hip fracture and limited mobility. Your patient is 64 inches tall and
weighs 115 pounds. She is postmenopausal. Her meds include OCP and a
multivitamin daily; her DEXA scan shows a T score of 1.3 and a Z score of -.8.
which exercise regimen is going to be most helpful to improve her bone health?
A. Stair climbing
B. Cycling
C. Water aerobics
D. Yoga
,E. Spin class
F. Running
G. A, D and F
H. A and F
G. A, D and F
68 y/o man with several risk factors for osteoporosis— cigarette smoking, drinking
3-5 alcoholic drinks/day, low body weight and sedentary lifestyle. Labs reveal a 25
Vitamin D level of 18 mcg. Of the following, what will you recommend?
A. Increase dietary intake of milk, eggs and catfish
B. Increase sun exposure
C. Calcium citrate with Vitamin D [200/200 IU] BID
D. Vitamin D2 50,000 IU daily for 6-12 months
E. Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then
5,000 IU thereafter
E. Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then 5,000 IU thereafter
Which agent [s] has/have a low likelihood of causing CV adverse effects in a
patient with BPH who is also taken meds for HTN?
1. Alfuzosin [Uroxatrol]
2. Tamulosin [Flomax]
3. Finasteride [Proscar]
A. 1 only
B. 2 only
,C. 3 only
D. 1 and 3
E. 2 and 3
F. 1, 2 and 3
E. 2 and 3
Stimulation of muscarinic cholinergic receptors in thbladder muscle may be
responsible for:
A. Functional incontinence
B. Urge incontinence
C. Bladder overactivity
D. Bladder underactivity
E. Both B and C are correct
Both B and C are correct
Which of the following drugs in most appropriate for managing incontinence
related to bladder overactivity?
A. Imipramine
B. Estrogens
C. Pseudoephedrine
D. Oxybutynin
E. Bethanechol
D. Oxybutynin
, Which of the following distinguishes the phosphodiesterase type 5 [PDE-5]
inhibitor Tadalafil
[Cialis] from the other inhibitors Sildenafil [Viagra] and Vardenafil [Levitra]?
A. Efficacy
B. Safety
C. Duration of Action
D. All of the above
C. Duration of Action
Which of the following is NOT a desired characteristic of a therapy for ED?
A. Leads to a prolonged erection [>4 hours]
B. Minimal side effects
C. Convenient administration
D. Quick onset of action
E. Few drug interactions
A. Leads to a prolonged erection [>4 hours]
What is the MOA of the PDE-5 inhibitors?
A. Increase prostaglandin production
B. Enhance effect of nitric oxide
C. Cause vasoconstriction of the erection chamber
D. Antagonize cyclic GMP
B. Enhance effect of nitric oxide
